Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C C Chan

Showing results (721-730 of 734) with videos related to

Pageof 74
Sort By:
Pathogens (Basel, Switzerland)|April 23, 2022
Mucosal Antibody Response to SARS-CoV-2 in Paediatric and Adult Patients: A Longitudinal StudyRenee W Y Chan, Kate C C Chan, Grace C Y Lui, et al.
Blood Advances|May 26, 2023
Clonal hematopoiesis in survivors of childhood cancerDanielle Novetsky Friedman, Irenaeus C C Chan, Chaya S Moskowitz, et al.
Human & Experimental Toxicology|August 8, 2008
Iron-generated hydroxyl radicals kill retinal cells in vivo: effect of ferulic acidH M Chao, Y H Chen, J H Liu, et al.
British Journal of Pharmacology|May 1, 1997
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitorD Riendeau, M D Percival, S Boyce, et al.
The World Allergy Organization Journal|December 6, 2024
Comparing pharmacists versus allergists in low-risk penicillin allergy delabelling: The Hong Kong Penicillin Allergy Pharmacist Initiative (HK-PAPI)James K Y Hooi, Marshall C H Low, Jonathan C L To, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2D Riendeau, M D Percival, C Brideau, et al.
Genome|March 4, 2000
Gene content and organization of a 281-kbp contig from the genome of the extremely thermophilic archaeon, Sulfolobus solfataricus P2R L Charlebois, R K Singh, C C Chan-Weiher, et al.
Bioinformatics (Oxford, England)|March 14, 2024
ArCH: improving the performance of clonal hematopoiesis variant calling and interpretationIrenaeus C C Chan, Alex Panchot, Evelyn Schmidt, et al.
Pageof 74

Showing results (721-730 of 734) with videos related to

Sort By:
Pageof 74
Pathogens (Basel, Switzerland)|April 23, 2022
Mucosal Antibody Response to SARS-CoV-2 in Paediatric and Adult Patients: A Longitudinal StudyRenee W Y Chan, Kate C C Chan, Grace C Y Lui, et al.
Blood Advances|May 26, 2023
Clonal hematopoiesis in survivors of childhood cancerDanielle Novetsky Friedman, Irenaeus C C Chan, Chaya S Moskowitz, et al.
Human & Experimental Toxicology|August 8, 2008
Iron-generated hydroxyl radicals kill retinal cells in vivo: effect of ferulic acidH M Chao, Y H Chen, J H Liu, et al.
British Journal of Pharmacology|May 1, 1997
Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitorD Riendeau, M D Percival, S Boyce, et al.
The World Allergy Organization Journal|December 6, 2024
Comparing pharmacists versus allergists in low-risk penicillin allergy delabelling: The Hong Kong Penicillin Allergy Pharmacist Initiative (HK-PAPI)James K Y Hooi, Marshall C H Low, Jonathan C L To, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 1999
Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profilesC C Chan, S Boyce, C Brideau, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 1999
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitorP Prasit, Z Wang, C Brideau, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2D Riendeau, M D Percival, C Brideau, et al.
Genome|March 4, 2000
Gene content and organization of a 281-kbp contig from the genome of the extremely thermophilic archaeon, Sulfolobus solfataricus P2R L Charlebois, R K Singh, C C Chan-Weiher, et al.
Bioinformatics (Oxford, England)|March 14, 2024
ArCH: improving the performance of clonal hematopoiesis variant calling and interpretationIrenaeus C C Chan, Alex Panchot, Evelyn Schmidt, et al.
Pageof 74